全文获取类型
收费全文 | 26861篇 |
免费 | 2518篇 |
国内免费 | 975篇 |
专业分类
耳鼻咽喉 | 301篇 |
儿科学 | 452篇 |
妇产科学 | 826篇 |
基础医学 | 3181篇 |
口腔科学 | 428篇 |
临床医学 | 3087篇 |
内科学 | 4669篇 |
皮肤病学 | 474篇 |
神经病学 | 1394篇 |
特种医学 | 868篇 |
外国民族医学 | 3篇 |
外科学 | 3605篇 |
综合类 | 2709篇 |
现状与发展 | 4篇 |
一般理论 | 4篇 |
预防医学 | 1897篇 |
眼科学 | 576篇 |
药学 | 2627篇 |
8篇 | |
中国医学 | 1136篇 |
肿瘤学 | 2105篇 |
出版年
2024年 | 73篇 |
2023年 | 325篇 |
2022年 | 747篇 |
2021年 | 1096篇 |
2020年 | 765篇 |
2019年 | 793篇 |
2018年 | 876篇 |
2017年 | 712篇 |
2016年 | 695篇 |
2015年 | 989篇 |
2014年 | 1231篇 |
2013年 | 1403篇 |
2012年 | 1966篇 |
2011年 | 2027篇 |
2010年 | 1353篇 |
2009年 | 1117篇 |
2008年 | 1496篇 |
2007年 | 1450篇 |
2006年 | 1338篇 |
2005年 | 1348篇 |
2004年 | 1131篇 |
2003年 | 1122篇 |
2002年 | 1036篇 |
2001年 | 879篇 |
2000年 | 713篇 |
1999年 | 570篇 |
1998年 | 259篇 |
1997年 | 235篇 |
1996年 | 167篇 |
1995年 | 130篇 |
1994年 | 121篇 |
1993年 | 87篇 |
1992年 | 228篇 |
1991年 | 223篇 |
1990年 | 184篇 |
1989年 | 151篇 |
1988年 | 127篇 |
1987年 | 152篇 |
1986年 | 114篇 |
1985年 | 97篇 |
1984年 | 83篇 |
1983年 | 64篇 |
1980年 | 40篇 |
1979年 | 60篇 |
1978年 | 49篇 |
1977年 | 43篇 |
1976年 | 39篇 |
1975年 | 38篇 |
1974年 | 50篇 |
1972年 | 60篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
目的探讨脑卒中患者急性应激障碍发生现状及影响因素。方法采用斯坦福急性应激反应问卷对349例脑卒中住院患者进行调查。结果共163例(46.70%)患者发生急性应激障碍;Logistic回归分析结果显示,患者性格、是否存在偏瘫及是否吞咽功能障碍是脑卒中患者发生急性应激障碍的主要影响因素(P0.05,P0.01)。结论脑卒中患者急性应激障碍发生率较高,内向性格及存在偏瘫和吞咽功能障碍的患者更容易发生急性应激障碍。医护人员应及时为高危患者提供个体化治疗及预见性护理,防止脑卒中患者发生急性应激障碍。 相似文献
4.
目的探究肿瘤坏死因子-α(Tumornecrosis factor-α,TNF-α)-308基因对导管相关性脓毒症(Catheter related sepsis,CRS)患者病情的影响,旨在为临床治疗CRS提供科学依据。方法选取2017年7月-2018年10月于浙江大学医学院附属杭州市第一人民医院接受治疗的86例CRS患者为研究对象,按照是否并发多器官功能障碍综合征将患者分为试验组和对照组,对照组共48例,未并发多器官功能障碍综合征,试验组共38例,并发多器官功能障碍综合征,分析两组患者TNF-α-308基因多态性差异,使用多因素Logistic回归分析CRS患者并发多器官功能障碍综合征的危险因素。结果试验组GA基因型频率34.21%、AA基因型频率50.00%、高G等位基因频率18.42%均高于对照组,GG基因型频率52.63%、A等位基因频率28.95%均低于对照组,差异均具有统计学意义(P<0.05);多因素Logistic回归分析结果显示,低GG基因型频率、低G等位基因频率、高GA基因型频率、高AA基因型频率、高A等位基因频率是CRS患者并发多器官功能障碍综合征的危险因素(P<0.05)。结论TNF-α-308基因与CRS患者病情密切相关,GG基因型频率和G等位基因频率降低,GA基因型频率、AA基因型频率、A等位基因频率升高会加重患者的病情,增加多器官功能障碍综合征的发生风险,临床上应该加以重视。 相似文献
5.
6.
Chih-Wei Hsu Sheng-Yu Lee Yao-Hsu Yang Liang-Jen Wang 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(10):653
BackgroundGeneric antidepressants are approved on the market based on evidence of bioequivalence to their brand-name versions. We aimed to assess whether generic antidepressants exert equal effectiveness as their brand-name counterparts for treating patients with depressive disorders.MethodsIn a nationwide, population-based cohort in Taiwan from 1997 through 2013, patients with a diagnosis of a depressive disorder aged between 18 and 65 years who were new users of antidepressant drugs were classified into either the brand-name group or the generic group. All patients were followed up until medication discontinuation or the end of the study period. We assessed the risk for hospitalization as a primary outcome and augmentation therapy, daily dose, medication discontinuation, or switching to another antidepressant as secondary outcomes.ResultsA total of 277 651 brand-name users (35.8% male; mean age: 41.2 years) and 270 583 generic users (35.8% male; mean age: 41.0 years) were divided into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, mirtazapine, moclobemide, imipramine, and bupropion). We found that patients treated with the generic form of sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, and bupropion demonstrated significantly higher risks of psychiatric hospitalization (adjusted hazard ratios ranged from 1.20–2.34), compared to their brand-name counterparts. The differences between brand-name antidepressants and their generic counterparts in secondary outcomes varied across different drugs.ConclusionsCompared to most generic antidepressants, brand-name drugs exhibited more protective effects on psychiatric hospitalization for depressive patients. These findings could serve as an important reference for clinicians when encountering patients with depressive disorder. 相似文献
7.
8.
Hsien-Chi Liao Jen-Hao Chuang Hsao-Hsun Hsu Ke-Cheng Chen Jin-Shing Chen 《Surgical endoscopy》2020,34(4):1641-1647
Thoracic empyema in uremic patients on maintenance hemodialysis is a challenging situation. The clinical characteristics are rarely reported, and the surgical outcomes remain unclear. We report our experience with video-assisted thoracoscopic surgery in these patients during 10-year period of time. Between 2005 and 2015, we retrospectively reviewed the clinical characteristics, bacteriological studies, and thoracoscopic surgical results of 23 empyema patients undergoing maintenance hemodialysis. The mean patient age was 67.1 ± 12.9 years. All patients had additional preexisting systemic diseases. The mean duration of hemodialysis was 34.7 ± 25.8 months. The infections causing empyema were pneumonia in 11 (47.8%), blood stream infection in 8 (34.8%), and uremic pleuritis in 4 (17.4%). Among the 22 identified microorganisms, the most common pathogen was methicillin-resistant Staphylococcus aureus (31.8%). After thoracoscopic surgery, 8 patients (34.8%) required additional procedures for complications, including 2 patients who required repeated thoracoscopy for hemothorax and 6 (26.1%) patients who required open drainage for residual empyema. The mean hospital stay was 62.4 days, and 6 patients (26.1%) died in the hospital. Univariate and multivariate analyses revealed that maintenance hemodialysis longer than 5 years was a significant factor associated with in-hospital mortality (odds ratio: 14.8, 95% confidence interval 1.5–151.6; p < 0.0001). While surgical management of thoracic empyema in uremic patients undergoing maintenance hemodialysis is associated with high rates of complication and mortality, thoracoscopic surgery is feasible, especially for patients undergoing hemodialysis for less than 5 years. 相似文献
9.
随着腹腔镜肝切除技术的发展与推广,腹腔镜肝切除中的一些难点,如术中出血的控制、解剖性肝切除、巨大肝癌切除、腹腔镜下联合肝脏分割与门静脉支结扎的二步肝切除术(ALPPS)等方面均基本解决。术中超声与荧光染色技术也得到普及。本文就上述问题做一概述,并对腹腔镜肝切除未来发展提出思路,以进一步推动我国腹腔镜肝切除的技术进步。 相似文献
10.
Mei-Yi Wu Yu-Wei Chen Lie-Yee Hung Chii-Hong Lee Hsin-An Chen Yung-Ho Hsu Mai-Szu Wu 《Transplantation proceedings》2019,51(5):1472-1474
IntroductionThe immunosuppressant agents in kidney transplantation (KT) may lead to various complications such as opportunistic infections and malignancies. BK virus associated nephropathy is a significant complication following KT, and it can result in graft failure. BK virus causes tubulointerstitial nephritis, ureter stenosis, and even graft failure in KT recipients with impaired immune system. We described a 63-year-old woman, who was a hepatitis C carrier and on dialysis for 22 years before KT, who received cadaveric-donor KT 2 years previously. She reported decreasing urine output and general weakness. The serum creatinine level was slightly increased from 2.94 to 4.38 mg/dL.MethodsImmunosuppressant medications including prednisolone, everolimus, cyclosporin, and mycophenolate sodium were continued as maintenance therapy post KT. Kidney biopsy was performed due to deterioration of graft function.ResultsThe kidney biopsy showed consistent results with early-stage polyomavirus nephropathy, characterized by focal viral cytopathic changes with positive immunohistochemical signals and mesangial proliferative glomerulonephritis, immune-complex-mediated (Fig 1 and Fig 2). Negative C4d staining at peritubular capillary was reported. The dosage of mycophenolate sodium was tapered from 720 to 360 mg daily and that of everolimus increased from 0.5 to 1.0 mg daily due to BK viral infection with BK nephropathy. The serum creatinine level was 2.75 mg/dL after treatment.ConclusionEarly detection of BK nephropathy and decreasing immunosuppressant agents are the mainstay of treatment. Substituting leflunomide for mycophenolate sodium and increasing dosage of everolimus has been proposed to solve BK nephropathy. We presented that the use of leflunomide in such situation is in a timely manner. 相似文献